Daniela Marino - Knight Therapeutics Global Compliance

All Insiders . USA . 
Stock . Knight Therapeutics . Stakeholders . Insider . Daniela Marino
KHTRF Stock  USD 3.73  0.04  1.08%   

Insider

Daniela Marino is Global Compliance of Knight Therapeutics
Phone514 484 4483
Webhttps://www.gud-knight.com

Knight Therapeutics Management Efficiency

The company has return on total asset (ROA) of (0.0133) % which means that it has lost $0.0133 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.0266) %, meaning that it generated substantial loss on money invested by shareholders. Knight Therapeutics' management efficiency ratios could be used to measure how well Knight Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.
Knight Therapeutics has accumulated 9.27 M in total debt with debt to equity ratio (D/E) of 0.05, which may suggest the company is not taking enough advantage from borrowing. Knight Therapeutics has a current ratio of 2.49, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Knight Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Knight Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Knight Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Knight to invest in growth at high rates of return. When we think about Knight Therapeutics' use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Scott CADiaMedica Therapeutics
59
Michael PitznerMolecular Partners AG
N/A
MD MBARezolute
N/A
RAC SakaiTempest Therapeutics
N/A
Steven RuhlForte Biosciences
67
Christopher RoenfeldtForte Biosciences
N/A
Thomas SchwerzmannMolecular Partners AG
N/A
Robyn SweinhartRezolute
N/A
Edward CalamaiDiaMedica Therapeutics
N/A
Justin TrojanowskiTempest Therapeutics
36
Dominic CundariDiaMedica Therapeutics
73
Andreas EMBAMolecular Partners AG
58
Dr DubenskyTempest Therapeutics
66
Brian MDRezolute
49
Joseph HazeltonDyadic International
48
, MBAMolecular Partners AG
51
Antony CPAForte Biosciences
57
Daniel RyweckSilo Pharma
59
Petpiboon PrasitTempest Therapeutics
N/A
Alexander ZurcherMolecular Partners AG
49
Seth LewisMolecular Partners AG
N/A
Knight Therapeutics Inc., a specialty pharmaceutical company, develops, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices in Canada, Latin America, and internationally. Knight Therapeutics Inc. was incorporated in 2013 and is headquartered in Montreal, Canada. Knight Therapeutics operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange. It employs 660 people. Knight Therapeutics [KHTRF] is a Pink Sheet which is traded between brokers as part of OTC trading.

Management Performance

Return On Equity-0.0266
Return On Asset-0.0133

Knight Therapeutics Leadership Team

Elected by the shareholders, the Knight Therapeutics' board of directors comprises two types of representatives: Knight Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Knight. The board's role is to monitor Knight Therapeutics' management team and ensure that shareholders' interests are well served. Knight Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Knight Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
BA BA, Ex Chairman
Arvind Utchanah, Chief Officer
Leopoldo Bosano, VicePres Operations
Susan Emblem, Global HR
Jody Engel, Sr Devel
Jeff Martens, Global Commercial
Daniela Marino, Global Compliance

Knight Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Knight Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity-0.0266
Return On Asset-0.0133
Profit Margin(0.09) %
Operating Margin(0.08) %
Current Valuation354.32 M
Shares Outstanding113.96 M
Shares Owned By Insiders30.54 %
Shares Owned By Institutions12.90 %
Price To Earning15.30 X
Price To Book0.69 X

Currently Active Assets on Macroaxis

RSIRush Street Interactive
OKTAOkta Inc
BACBank of America
SSentinelOne
WDWalker Dunlop

Other Information on Investing in Knight Pink Sheet

Knight Therapeutics financial ratios help investors to determine whether Knight Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Knight with respect to the benefits of owning Knight Therapeutics security.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY